Bivalirudin for percutaneous coronary intervention and in acute coronary syndromes.

Article Details

Citation

Copy to clipboard

Bates ER

Bivalirudin for percutaneous coronary intervention and in acute coronary syndromes.

Curr Cardiol Rep. 2001 Sep;3(5):348-54.

PubMed ID

11504570 [ View in PubMed

]

Abstract

This review focuses on the use of bivalirudin as a replacement anticoagulant for heparin in patients undergoing percutaneous coronary intervention, or who are being treated for unstable angina pectoris, ST-elevation, or non-ST-elevation myocardial infarction. Potential advantages of bivalirudin include a lack of dependence on antithrombin III for anticoagulant activity, the ability to inactivate both fibrin-bound and soluble thrombin, a lack of aggregatory effects on platelets, a predictable anticoagulant response without monitoring, and a wider therapeutic window. Clinical trial results to date suggest that bivlirudin is at least as effective as heparin with superior safety due to lower bleeding rates.

DrugBank Data that Cites this Article

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Bivalirudin	Prothrombin	Protein	Humans	Yes	Inhibitor	Details